Blakely, Collin M <br/><br/>
Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.  [electronic resource] 

 -  Cancer discovery  Oct 2012 
 - 872-5 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2159-8290 
<br/><br/><label>Standard No.: </label>10.1158/2159-8290.CD-12-0387  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cell Line, Tumor<br/>Class I Phosphatidylinositol 3-Kinases<br/>Drug Resistance, Neoplasm--genetics<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Gefitinib<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Molecular Targeted Therapy<br/>Mutation<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Protein Kinase Inhibitors--pharmacology<br/>Quinazolines--therapeutic use<br/>Receptor, ErbB-2--biosynthesis